111615_SK Invite_Final

Symposium MC: Prof. Howard Lee, SNUH
Time
Title
Speaker
1:00-1:30pm
Registration
1:30-1:40pm
Welcome Statement
1:40-2:00pm
Special Session: What is the Point of MFDS for IND Approval?
Prof. In-Jin Jang
SNUH
Yang Su Park
Director & Principal Consultant
MediTip
Session 1: Innovative Study Designs to De-Risk Early Clinical Studies
Chair: Dr. Kwan-Sung Kim, Director General, Pharmaceutical Safety Bureau of MFDS
2:00-2:30pm
Incorporating Early Assessments of Cardiovascular and CNS
Safety into Early Clinical Studies
2:30-3:00pm
Imaging in Preclinical and Early Clinical Studies
3:00-3:10pm
Q&A Session
3:10-3:30pm
Coffee Break
Dr. Bruce Morimoto
Executive Director, Applied Translational Medicine
Celerion
Prof. Keon Wook Kang
SNUH
Session 2: Innovation in Understanding the Clinical Pharmacology of Oncology Drugs
Chair: Dr. Deborah Chee, President, KoNECT
3:30-4:00pm
Can Oncology Drugs be Studied in Healthy Subjects?
4:00-4:30pm
Innovative Technologies for Early Understanding of Antitumor
Efficacy of New Agents
4:30-4:40pm
Q&A Session
4:40-4:45pm
Closing Remarks
Elliot Offman MS
Senior Director, Clinical Pharmacology Sciences
Celerion
Prof. Yung-Jue Bang
SNUH
Dr. Bruce Morimoto
Executive Director, Applied Translational Medicine
Celerion